Ionis Pharmaceuticals, Inc. (IONS)
- Previous Close
29.81 - Open
31.82 - Bid 30.56 x 300
- Ask 30.86 x 100
- Day's Range
29.85 - 31.82 - 52 Week Range
23.95 - 52.34 - Volume
1,915,184 - Avg. Volume
1,728,460 - Market Cap (intraday)
4.869B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-3.04 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
57.31
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
www.ionis.comRecent News: IONS
View More
Performance Overview: IONS
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IONS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IONS
View MoreValuation Measures
Market Cap
4.74B
Enterprise Value
3.86B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.32
Price/Book (mrq)
8.05
Enterprise Value/Revenue
5.47
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.37%
Return on Assets (ttm)
-9.91%
Return on Equity (ttm)
-93.10%
Revenue (ttm)
705.14M
Net Income Avi to Common (ttm)
-453.9M
Diluted EPS (ttm)
-3.04
Balance Sheet and Cash Flow
Total Cash (mrq)
2.3B
Total Debt/Equity (mrq)
332.93%
Levered Free Cash Flow (ttm)
-352.83M
Research Analysis: IONS
View MoreResearch Reports: IONS
View MoreIonis Earnings: Tryngolza Commercial Launch Underway; Shares Very Undervalued
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
RatingPrice TargetDaily – Vickers Top Buyers & Sellers for 01/21/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, same-store NOI continues to decelerate for many US real estate sectors; medtech moat review reveals importance of switching costs; consensus regarding Etsy's midterm growth prospects is too pessimistic; and Ionis, Nike, and Pfizer.
Ionis: FDA Approves Rare-Disease Drug Tryngolza; Shares Undervalued for Long-Term Investors
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
RatingPrice Target